S. Shalaby, M., I. Salama, M., E. Badr, R., M. Hassan, A., S. Ahmed, A., S. Omar, A. (2018). Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity. Suez Canal University Medical Journal, 21(2), 132-139. doi: 10.21608/scumj.2018.43593
Mai S. Shalaby; Mona I. Salama; Rasha E. Badr; Amany M. Hassan; Amal S. Ahmed; Aziza S. Omar. "Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity". Suez Canal University Medical Journal, 21, 2, 2018, 132-139. doi: 10.21608/scumj.2018.43593
S. Shalaby, M., I. Salama, M., E. Badr, R., M. Hassan, A., S. Ahmed, A., S. Omar, A. (2018). 'Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity', Suez Canal University Medical Journal, 21(2), pp. 132-139. doi: 10.21608/scumj.2018.43593
S. Shalaby, M., I. Salama, M., E. Badr, R., M. Hassan, A., S. Ahmed, A., S. Omar, A. Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity. Suez Canal University Medical Journal, 2018; 21(2): 132-139. doi: 10.21608/scumj.2018.43593
Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity
1Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt
2Department of Clinical Pathology, Faculty of Medicine, Port Said University, Egypt
3Department of Clinical Pathology, Faculty of Medicine, Port Said University Egypt,
4Department of Clinical Pathology, Faculty of Medicine, Suez Canal University
5Department of Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Egypt
Abstract
Background: Rheumatoid Arthritis (RA) is a chronic progressive, systemic inflammatory, connective tissue disease affecting approximately 1% of the general population. Interleukin-33 (IL33), a member of the IL-1 family, is a ligand for the orphan receptor ST2 (known as IL-1RL1 also). IL-33 is crucial for Th2 cytokine-mediated immune responses however; it can overcome this role in RA. Aim: This study aimed to investigate the potential role of inflammatory cytokine (IL-33) in RA and assess the correlation of IL-33 level to disease activity. Subjects and Method: The study included sixty patients with RA. Patients were diagnosed according to the American College of Rheumatology (ACR) 2010 revised criteria and were classified into 2 groups of 30 patients each according to disease activity score 28 (DAS28), the first group included RA patients with DAS28 of ≤2.4 and the second group included RA patients with DAS28 >2.4.Thirty normal subjects served as a control group. Serum IL-33 was measured using ELISA. Results: Serum IL33 level was significantly higher in patient's group compared to the control group (P ≤.001). Also, serum IL33 level, was significantly higher in patients’ group 2 (DAS>2.4) than patients’ group 1 (DAS≤2.4) (P<0.001). Serum IL-33 level positively correlated with disease duration, ESR, CRP and disease severity. Conclusion: IL-33 is a novel potential marker for the risk of RA as well as a marker of disease activity
View on SCiNiTO
Top